Contribute Try STAT+ Today

Flagship Pioneering, the Cambridge, Mass., venture capital firm, brought biotech startup Laronde out of stealth mode in May, launching it with $50 million after four years of secrecy.

It was the first time Laronde disclosed its technology: a proprietary molecule its scientists call “endless RNA,” which the company hopes will allow humans to produce their own proteins for weeks or months to treat diseases. Now, three months after making its public debut, Laronde announced it has raised $440 million from investors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment